Sleep & Conditions
Does cannabis actually help with chronic pain in older adults?
Research summary prepared with AI assistance · Not authored by Ken Feldman or Nadine Laham · For general information only
~10 minute read
The short answer
Cannabis for chronic pain is the most-studied therapeutic claim, and the evidence is genuinely promising — particularly for nerve pain (neuropathic pain) and pain associated with multiple sclerosis. For other types of pain — back pain, fibromyalgia, arthritis pain — the evidence is weaker and more mixed. The clinically meaningful effect, when it exists, is real but modest. Cannabis is unlikely to be a complete pain solution, but for some patients it offers a useful adjunct that allows lower doses of other medications.
Why pain is the most-studied cannabis question
Chronic pain affects roughly 25% of adults over 65, and the standard pharmacological options all have meaningful drawbacks for older patients: NSAIDs raise cardiovascular and gastrointestinal bleeding risk; opioids carry addiction and overdose concerns and produce confusion, constipation, and falls; gabapentin and pregabalin can cause sedation and cognitive fog. The need for additional options is real, and that need has driven a substantial research effort into cannabis as one of those options.
The result: there are now hundreds of studies on cannabis and pain, dozens of systematic reviews, and even a 2017 National Academies of Sciences report concluding that cannabis or cannabinoids are “effective” for chronic pain in adults — one of the few cannabis claims that report endorsed at that level.
What the research actually shows
The picture is more nuanced than headlines suggest. Let’s break it down by pain type.
Neuropathic pain (nerve pain)
This is the strongest evidence area. Multiple randomized controlled trials show that cannabis produces a clinically meaningful reduction in neuropathic pain compared to placebo. The conditions where this has been most studied include diabetic peripheral neuropathy, post-shingles pain, HIV-related neuropathy, and multiple sclerosis-related pain.
The effect size is real but not transformative — typical pain reductions of 30-40% in responders, with a substantial portion of patients (40%+) not responding meaningfully at all. This is roughly comparable to the effect size of gabapentin or duloxetine for the same conditions.
Back pain and musculoskeletal pain
The evidence here is weaker. Studies show modest pain reductions on average, but the effects are smaller and less consistent than for neuropathic pain. Some patients report substantial benefit; many report little to none. This is squarely in Promising Evidence territory rather than Medically Documented.
Arthritis pain
Surprisingly, given how often cannabis is marketed for arthritis, the human research on cannabis for osteoarthritis pain specifically is relatively thin. Animal studies are encouraging; rigorous human trials are few. Topical CBD products marketed for arthritis joints have very limited evidence behind them — most CBD applied to skin doesn’t reach the underlying joint in meaningful concentrations.
Fibromyalgia
Some patients with fibromyalgia report substantial benefit from cannabis. Controlled trials show smaller, less consistent effects. The fibromyalgia population is heterogeneous enough that average results may be hiding a subgroup of strong responders.
Cancer pain
Cannabis has documented benefits for chemotherapy-induced nausea (separate question) and may help with some cancer-related pain, particularly when added to existing opioid regimens. It’s not a substitute for cancer pain management but can be a useful addition in some cases.
The opioid-sparing question
One of the more interesting findings in the cannabis-pain literature is that adding cannabis to an existing pain regimen may allow some patients to reduce their opioid dose without losing pain control. This is called “opioid-sparing” and is a major part of why some clinicians who would not have prescribed cannabis in 2010 will now consider it for selected patients in 2026.
The catch: it works for some patients and not others, and predicting who will benefit is currently more art than science.
Worth knowing: The most useful cannabis for chronic pain is rarely the highest-THC product. Many older patients find that lower-THC, balanced or CBD-dominant products produce meaningful pain modulation with less of the cognitive effect that interferes with daily life. The dispensary's most potent flower is not the most therapeutic option.
What does not work as well as advertised
Several pain-related cannabis claims have outpaced the evidence:
- Topical CBD for joint pain. Limited skin penetration, weak evidence base.
- CBD-only products for moderate-to-severe pain. CBD’s pain effects appear to require higher doses than most retail products contain.
- Cannabis as a primary treatment for severe pain. The effect size is too modest for it to replace stronger interventions in most cases.
- “Specific strain” claims (“Indica for pain, sativa for energy”). The strain naming system is largely unrelated to cannabinoid content and the alleged effects don’t hold up in studies.
The realistic frame for older adults
If you have chronic pain, are over 65, and are considering cannabis as part of your approach, a reasonable framing is: cannabis is one of several pain tools that may produce a meaningful but partial benefit, with a side effect profile that is generally better tolerated than opioids but worse than acetaminophen. It is most useful as an addition to an existing approach, less often as a complete replacement, and works better for some pain types than others.
The conversation with your pain doctor or primary care doctor is worth having before you experiment on your own — not because they have to “approve” of it, but because they have information about your specific situation that affects whether this is likely to help.
What the evidence says
For neuropathic pain specifically, the evidence rating is Medically Documented with caveats about effect size. For other pain types, Promising Evidence is the most accurate label — real signal, but not yet definitive. The marketing-driven claim that “cannabis works for pain” oversimplifies a real but uneven literature.
Discuss with your doctor
- What type of pain you have (nerve, musculoskeletal, inflammatory, mixed) — this affects whether cannabis is likely to help
- What pain management options have been tried and what is currently working
- Whether cannabis might allow reduction of an existing opioid or other pain medication dose
- What functional outcomes matter to you (sleep, mobility, mood) beyond just the pain score
- How long to give a cannabis trial before deciding it isn't working